| Code | CSB-RA015007MB18HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Rituximab-ABBS, targeting MS4A1 (CD20), a transmembrane phosphoprotein exclusively expressed on the surface of B lymphocytes from pre-B to mature B cell stages. MS4A1 plays a critical role in regulating B cell activation, proliferation, and differentiation through modulation of calcium influx and cell cycle progression. This target is centrally implicated in B cell-mediated autoimmune disorders and B cell malignancies, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, making it a key therapeutic target for B cell depletion strategies.
Rituximab-ABBS is a biosimilar version of the original rituximab, a chimeric anti-CD20 monoclonal antibody that has been widely used in clinical and research settings for selective B cell depletion. This biosimilar antibody provides researchers with a cost-effective tool for investigating B cell biology, studying immune-mediated diseases, evaluating therapeutic mechanisms of B cell depletion, and developing novel immunotherapeutic approaches in preclinical models.
There are currently no reviews for this product.